Multiple Sclerosis Nerve Damage: Breakthrough Compounds Reverse Damage
- Multiple sclerosis (MS) is a long-term autoimmune condition that affects over 2.9 million people around the world.In MS, the immune system mistakenly attacks the myelin sheath, a protective...
- Currently, MS treatments focus on reducing inflammation but don't repair the damaged myelin sheath or protect neurons.
- The study was led by Seema Tiwari-Woodruff (UC Riverside) and John Katzenellenbogen (UIUC).
Potential Remyelination Therapies for Multiple Sclerosis Discovered
Table of Contents
Multiple sclerosis (MS) is a long-term autoimmune condition that affects over 2.9 million people around the world.In MS, the immune system mistakenly attacks the myelin sheath, a protective layer that insulates nerve fibers. This damage interrupts interaction between the brain and body, leading to symptoms such as numbness, tingling, vision problems, and paralysis.
The Challenge & The Breakthrough
Currently, MS treatments focus on reducing inflammation but don’t repair the damaged myelin sheath or protect neurons. Recent research, supported by the National Multiple sclerosis Society, has identified two compounds – K102 and K110 - that show promise in promoting remyelination, the repair of the myelin coating on nerve fibers.
Key Findings
- Compounds identified: K102 and K110, analogs of indazole chloride.
- Mechanism: Stimulate myelin repair and, in the case of K102, regulate immune activity.
- Testing: Demonstrated efficacy and safety in mouse models and human cells (oligodendrocytes derived from induced pluripotent stem cells).
- K102: Leading candidate for MS treatment due to its dual action (remyelination & immune regulation).
- K110: Potential for other neurological conditions like spinal cord injury or traumatic brain injury.
Research Details
The study was led by Seema Tiwari-Woodruff (UC Riverside) and John Katzenellenbogen (UIUC). it built upon previous work with indazole chloride, which showed initial promise but lacked the necessary properties for clinical growth. The team screened over 60 analogs of indazole chloride to identify K102 and K110.
The research was funded by the National MS Society through both standard grants and the Fast Forward program, which focuses on accelerating commercialization.
Compound Comparison
| Compound | Remyelination Potential | Immune Regulation | Potential Applications |
|---|---|---|---|
| K102 | High | Yes | Multiple Sclerosis |
| K110 | High | Limited | Spinal Cord Injury, Traumatic Brain injury |
When & Why This Matters
When: The study was published in Scientific Reports recently, building on over a decade of research with intensive work over the last four years. Clinical testing is anticipated in the near future.
Why: Current MS treatments only manage symptoms.Thes compounds offer the potential to repair damage caused by MS, potentially slowing or reversing disease progression and improving quality of life. The ability to remyelinate nerves is a major unmet need in MS treatment.
What’s Next
- Clinical Trials: Cadenza Bio,Inc. (licensed the technology) is preparing for clinical testing of K102.
- Further Development of K110: Continued inquiry of K110 for spinal cord injury and traumatic brain injury.
- Commercialization: The Fast Forward program’s support is crucial for bringing this potential therapy to market.